Haiping Jiang

1.7k total citations
45 papers, 796 citations indexed

About

Haiping Jiang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Haiping Jiang has authored 45 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Haiping Jiang's work include Gastric Cancer Management and Outcomes (9 papers), Gastrointestinal Tumor Research and Treatment (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Haiping Jiang is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Gastrointestinal Tumor Research and Treatment (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Haiping Jiang collaborates with scholars based in China, New Zealand and United Kingdom. Haiping Jiang's co-authors include Youqing Shen, Jianbin Tang, Zhuxian Zhou, Lisong Teng, Quan Zhou, Hongbo Guo, Jinming Yu, Hao Song, Shaoqing Chen and Jing Hua and has published in prestigious journals such as Advanced Materials, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Haiping Jiang

43 papers receiving 790 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haiping Jiang China 15 366 246 199 145 113 45 796
Zhilei Lv China 13 300 0.8× 303 1.2× 208 1.0× 209 1.4× 157 1.4× 25 935
Magdalena Jarosz–Biej Poland 15 321 0.9× 362 1.5× 126 0.6× 267 1.8× 169 1.5× 31 974
Joshua J. Souchek United States 16 326 0.9× 462 1.9× 201 1.0× 99 0.7× 245 2.2× 22 1.0k
Xiaoli Ju China 15 440 1.2× 347 1.4× 138 0.7× 327 2.3× 135 1.2× 28 919
Johanna Tuomela Finland 19 327 0.9× 537 2.2× 174 0.9× 188 1.3× 179 1.6× 49 984
Zhuangzhuang Zheng China 17 211 0.6× 312 1.3× 257 1.3× 160 1.1× 207 1.8× 39 851
Xuli Meng China 14 257 0.7× 489 2.0× 114 0.6× 128 0.9× 220 1.9× 43 792
Zhijuan Liang China 16 188 0.5× 405 1.6× 117 0.6× 181 1.2× 293 2.6× 31 839
Sahar Safaei Iran 15 287 0.8× 349 1.4× 103 0.5× 186 1.3× 185 1.6× 31 722

Countries citing papers authored by Haiping Jiang

Since Specialization
Citations

This map shows the geographic impact of Haiping Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiping Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiping Jiang more than expected).

Fields of papers citing papers by Haiping Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiping Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiping Jiang. The network helps show where Haiping Jiang may publish in the future.

Co-authorship network of co-authors of Haiping Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Haiping Jiang. A scholar is included among the top collaborators of Haiping Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiping Jiang. Haiping Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Haiping, Liying Qian, Jingwen Zhang, et al.. (2025). Predictive value of plasma sB7-H3 and YKL-40 in pediatric refractory Mycoplasma pneumoniae pneumonia. Open Medicine. 20(1). 20241114–20241114.
2.
An, Jusheng, Guiling Li, Jennifer Zhang, et al.. (2025). Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907). Gynecologic Oncology. 202. 33–40. 1 indexed citations
3.
Li, Ning, et al.. (2024). A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer. Scientific Reports. 14(1). 15150–15150. 1 indexed citations
4.
Wang, Jiafeng, Yechun Wang, Junjun Li, et al.. (2024). Neutrophil Extracellular Traps‐Inhibiting and Fouling‐Resistant Polysulfoxides Potently Prevent Postoperative Adhesion, Tumor Recurrence, and Metastasis. Advanced Materials. 36(31). e2400894–e2400894. 13 indexed citations
5.
Huang, Cheng, Haiping Jiang, Liyuan Jiang, et al.. (2024). Functional mouse hepatocytes derived from interspecies chimeric livers effectively mitigate chronic liver fibrosis. Stem Cell Reports. 19(6). 877–889. 2 indexed citations
6.
Wang, Haoyun, Xin Lv, Lipeng Mao, et al.. (2023). Hepatocellular carcinoma cell differentiation trajectory predicts immunotherapy, potential therapeutic drugs, and prognosis of patients. Open Life Sciences. 18(1). 20220656–20220656.
7.
Zhang, Jianli, Junyi Ye, Shurong Wang, et al.. (2023). En Bloc Resection for Spinal Cord Hemangioblastomas: Surgical Technique and Clinical Outcomes. Journal of Neurological Surgery Part A Central European Neurosurgery. 85(6). 577–584. 2 indexed citations
8.
Zhang, Dongzhi, Haiping Jiang, Junyi Ye, et al.. (2021). A novel lncRNA, RPL34-AS1, promotes proliferation and angiogenesis in glioma by regulating VEGFA. Journal of Cancer. 12(20). 6189–6197. 9 indexed citations
9.
Liu, Jing, Zhihao Zhao, Nasha Qiu, et al.. (2021). Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. Nature Communications. 12(1). 2425–2425. 123 indexed citations
10.
Hu, Shiqi, Haiping Jiang, Jinqiang Wang, et al.. (2020). Tumor-specific fluorescence activation of rhodamine isothiocyanate derivatives. Journal of Controlled Release. 330. 842–850. 11 indexed citations
11.
12.
13.
Fan, Weina, et al.. (2018). Esophageal metastasis from endometrial adenocarcinoma: a case report and literature review. Translational Cancer Research. 7(4). 1178–1183. 2 indexed citations
14.
Ying, Kejing, et al.. (2018). OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 13(12). S1047–S1047. 3 indexed citations
15.
Jiang, Haiping, Peng Zhao, Xiaochen Zhang, et al.. (2015). A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 76(1). 197–203. 3 indexed citations
16.
Zheng, Yulong, Weijia Fang, Chenyu Mao, et al.. (2014). Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study. Cancer Chemotherapy and Pharmacology. 74(3). 503–509. 3 indexed citations
17.
Jiang, Haiping. (2011). Differential protein expression during colonic adaptation in ultra-short bowel rats. World Journal of Gastroenterology. 17(20). 2572–2572. 4 indexed citations
18.
Jin, Ketao, Kuifeng He, Na Han, et al.. (2011). Establishment of a PDTT Xenograft Model of Gastric Carcinoma and its Application in Personalized Therapeutic Regimen Selection. Hepatogastroenterology. 58(110-111). 1814–22. 20 indexed citations
19.
Jiang, Haiping, Jinming Yu, Hongbo Guo, Hao Song, & Shaoqing Chen. (2007). Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochemical and Biophysical Research Communications. 368(1). 1–5. 64 indexed citations
20.
Kausch, Ingo, Haiping Jiang, Kirsten Bruderek, et al.. (2004). Ki-67-Directed Antisense Therapy in an Orthotopic Renal Cell Carcinoma Model. European Urology. 46(1). 118–125. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhilei Lv Breakdown of academic impact, for papers by Magdalena Jarosz–Biej Breakdown of academic impact, for papers by Joshua J. Souchek Breakdown of academic impact, for papers by Xiaoli Ju Breakdown of academic impact, for papers by Johanna Tuomela Breakdown of academic impact, for papers by Zhuangzhuang Zheng Breakdown of academic impact, for papers by Xuli Meng Breakdown of academic impact, for papers by Zhijuan Liang Breakdown of academic impact, for papers by Sahar Safaei
Rankless by CCL
2026